Roka Bioscience, Inc. (NASDAQ:ROKA) major shareholder Orbimed Advisors Llc sold 201,617 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $0.68, for a total transaction of $137,099.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Friday, September 29th, Orbimed Advisors Llc sold 474,676 shares of Roka Bioscience stock. The stock was sold at an average price of $0.72, for a total transaction of $341,766.72.
  • On Wednesday, September 27th, Orbimed Advisors Llc sold 127,601 shares of Roka Bioscience stock. The stock was sold at an average price of $0.98, for a total transaction of $125,048.98.
  • On Wednesday, August 23rd, Orbimed Advisors Llc sold 1,100 shares of Roka Bioscience stock. The stock was sold at an average price of $1.50, for a total transaction of $1,650.00.
  • On Thursday, August 24th, Orbimed Advisors Llc sold 14,300 shares of Roka Bioscience stock. The stock was sold at an average price of $1.50, for a total transaction of $21,450.00.
  • On Tuesday, August 22nd, Orbimed Advisors Llc sold 75,276 shares of Roka Bioscience stock. The stock was sold at an average price of $1.52, for a total transaction of $114,419.52.

Shares of Roka Bioscience, Inc. (ROKA) traded up 2.43% during trading on Friday, reaching $0.80. 70,415 shares of the company’s stock traded hands. Roka Bioscience, Inc. has a one year low of $0.66 and a one year high of $8.50. The company has a 50 day moving average price of $1.08 and a 200-day moving average price of $2.52. The stock’s market cap is $4.01 million.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/06/roka-bioscience-inc-roka-major-shareholder-orbimed-advisors-llc-sells-201617-shares.html.

An institutional investor recently raised its position in Roka Bioscience stock. Sabby Management LLC increased its holdings in shares of Roka Bioscience, Inc. (NASDAQ:ROKA) by 6.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 389,136 shares of the medical research company’s stock after buying an additional 23,916 shares during the period. Sabby Management LLC owned about 7.77% of Roka Bioscience worth $1,374,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 66.51% of the company’s stock.

Roka Bioscience Company Profile

Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.

Receive News & Stock Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related stocks with our FREE daily email newsletter.